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Abstract
Purpose of Review To provide an update on the use of cardiac magnetic resonance imaging in the diagnosis of Takotsubo
cardiomyopathy.
Recent Findings Long-term prognosis of Takotsubo cardiomyopathy may not be as clear-cut as previously thought. Cardiac
magnetic resonance imaging not only allows differentiation between reversible and nonreversible changes but has an emerging
role in identifying cellular level changes associated with prognostic indicators such as myocardial energetics using 31P-CMR
spectroscopy and detection of myocardial inflammation overlying myocardial oedema, using ultrasmall paramagnetic iron oxide
particle uptake in macrophages.
Summary Takotsubo cardiomyopathy is a non-ischemic acute heart failure syndrome. It is commonly triggered by emotional or
physical stress and is possibly the strongest psychosomatic interaction seen in medicine. While clinically its presentation mimics
a myocardial infarction, the acute imaging characteristics are critical in correctly identifying the disease entity.
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Introduction
Takotsubo cardiomyopathy, also known as acute stress-
induced cardiomyopathy, apical ballooning and broken heart
syndrome, was first described in 1990 in Japan by Sato et al.
Takotsubo cardiomyopathy mimics acute coronary syn-
dromes, presenting with symptoms, ECG changes and elevat-
ed biomarker levels that are indistinguishable from an acute
myocardial infarction. However, the imaging characteristics
and coronary angiography findings set it apart. As clinicians
become more aware of this disease entity, there has been an
exponential increase in its diagnosis [1]. Imaging in
Takotsubo has evolved hugely over the last decade with car-
diac magnetic resonance (CMR) imaging being the front run-
ner in terms of detection of myocardial oedema and
inflammation, fibrosis and cardiac energetic status in addition
to accurate cine imaging for ventricular volumes and mass.
The objective of this review is to present current medical
literature and evidence for the place of CMR in diagnosis of
Takotsubo, in unravelling its pathophysiology and informing
on the convalescent and long-term phases of the disease.
Proposed Pathophysiological Mechanism
of Takotsubo Cardiomyopathy
To date, the exact pathogenic mechanism of this syndrome
remains unclear; however, several hypotheses have been pro-
posed involving vascular mechanisms (i.e. abnormal coronary
epicardial or microvascular vasoreactivity) [2–4], endocrine
and gender-related mechanisms (i.e. oestrogen deficiency)
and both autonomic and central nervous system abnormalities
involving possible catecholamine surges [5, 6], suggesting the
possibility of a multifactorial pathogenic background.
Incidence, Clinical Presentation and Diagnosis
Takotsubo syndrome is estimated to represent approximately
1–3% of all [7] and 5–6% of the female patients presenting
with suspected acute myocardial infarction [8, 9].
This article is part of the Topical Collection on Cardiac Magnetic
Resonance
* Maheshi Y. Gunasekara
maheshi.gunasekara1@abdn.ac.uk
1 Medical Sciences and Nutrition, University of Aberdeen,
Aberdeen, UK
Current Cardiovascular Imaging Reports           (2020) 13:17 
https://doi.org/10.1007/s12410-020-09536-0
The diagnosis of Takotsubo has evolved in the past decade.
Initially, Mayo Clinic criteria proposed the combination of the
following: (1) transient, reversible regional wall motion ab-
normalities of the left ventricle (LV) extending beyond a sin-
gle epicardial coronary vascular distribution; (2) absence of
angiographic evidence of flow limiting coronary disease or
acute plaque rupture; (3) new changes in electrocardiogram
(ST segment elevation or Twave inversion); and (4) no recent
significant head trauma, intracranial bleeding, pheochromocy-
toma, obstructive epicardial coronary artery disease (CAD),
myocarditis and hypertrophic cardiomyopathy [10]. However,
these have gradually evolved, and currently, the European
Society of Cardiology has developed new international diag-
nostic criteria (InterTAK Diagnostic Criteria). These pertain
mainly to the addition of the fact that the presence of CAD
should not be considered as an exclusion criterion and is an
important recognized bystander. In such patients, the wall mo-
tion abnormalities may extend beyond the territory of the dis-
eased coronary artery. Takotsubo may also co-exist with acute
coronary syndromes [11], and in some cases, acute coronary
syndromes may trigger the onset of Takotsubo [12•]. A second
important addition to the guidelines is the recognition that
Takotsubo can co-exist with pheochromocytoma.
Pheochromocytoma is a neuroendocrine disorder which may
lead to a catecholamine storm with LV dysfunction, ECG
abnormalities, elevated cardiac biomarkers as well as wall
motion abnormalities which may be difficult to differentiate
from Takotsubo. Furthermore, an additional clinical pheno-
type, the focal Takotsubo involving a single myocardial seg-
ment, has also been recognized [13].
Cardiac MRI
Over the last decade, CMR has become the key diagnostic
modality in tertiary care centres for patients with suspected
Takotsubo. Typically, this is carried out on clinical field
strength scanners at 1.5 T or 3 T.
CMR is indicated in all patients presenting with suspected
Takotsubo; however, this is difficult to schedule in a timely
manner in busy clinical settings. Therefore, diagnostic and
management algorithms have been generated to help guide
clinical decision-making. While risk stratification is essential
to select patients, given the absence of evidence from large
randomized control trials, the algorithms are based on expert
consensus and require validation. Patients presenting with
myocardial infarction and unobstructed coronary arteries
(MINOCA) or without a clear culprit remain a diagnostic
challenge, and timely CMR in this subgroup has shown higher
prevalence of Takotsubo [14, 15]. In these, the presence of an
increased left ventricular mass, presence of intense myocardial
oedema and lack of any late gadolinium enhancement are
strongly in favour of a Takotsubo diagnosis.
It is the practice of the authors’ institution that patients with
troponin positive chest pain and absence of a clear culprit
lesion on coronary angiogram are further risk stratified based
on left ventriculogram and echocardiogram and specifically
those with atypical ballooning patterns are fast tracked to early
CMR. ECG changes in the post-acute phase with significantly
greater T wave amplitude which is also widespread in a 12-
lead ECG 24–48 h after presentation, accompanied by in-
creases in QTc interval which is also a valuable tool in differ-
entiating Takotsubo from MI [16]. ST depression in aVR and
absence of ST elevation in V1 has been shown to suggest
Takotsubo with sensitivity and specificity of > 90% [17].
Troponin elevation is usually disproportionally low to the ex-
tent of the myocardium involved, while NT-proBNP levels are
higher at admission compared with acute coronary syndromes
[18]. International expert consensus document provides a
comprehensive diagnostic algorithm which can be used to
differentiate Takotsubo vs acute coronary syndromes or myo-
carditis [19].
General Utility and Sequences Used
Cardiovascular magnetic resonance imaging is uniquely suit-
ed for the evaluation of patients with Takotsubo. In addition to
accurate visualization of regional wall motion abnormalities, it
allows for precise quantification of right ventricular (RV) and
LV function and the assessment of other abnormalities (e.g.
pericardial and pleural effusion, LV and RV thrombi).
Importantly, CMR imaging also allows differentiation of re-
versible (inflammation, oedema) and irreversible (necrosis,
fibrosis) injury, which may be particularly important to verify
Takotsubo and to exclude similar acute cardiac diseases such
as myocardial infarction or myocarditis [20].
Due to its versatility, several sequences have become a
routine in the clinical investigation of Takotsubo, while others
have been tested in the clinical research environment only. For
clinical assessment, steady-state free precession imaging is
used for volumetric assessment of the cardiac chambers and
appreciation of segmental wall motion abnormalities. T2-
weighted imaging (T2W) with fat suppression (triple inver-
sion recovery) is utilized for qualitative assessment of myo-
cardial oedema. Further, T1 and T2 myocardial mapping are
used for quantification of oedema during the acute phase of
the disease. T1 mapping is also used for quantification of
myocardial fibrosis once the myocardial oedema has subsid-
ed. Early gadolinium enhancement (EGE) is utilized to iden-
tify LV thrombi, whereas late gadolinium enhancement (LGE)
images acquired 10–20 min after administration of contrast
are used to rule out myocardial infarction or any other macro-
scopic fibrosis patterns that would point out to a different
pathology. In clinical research, cardiac 31P-magnetic reso-
nance spectroscopy has been used to assess the cardiac ener-
getic status, and T2*-based sequences have identified
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myocardial inflammation by tracking ultrasmall iron oxide
particles phagocytosed by activated macrophages in the
myocardium.
Functional Assessment
Left Ventricular Function and Typical Wall Motion
Abnormalities One of the most relevant features and a key
diagnostic criterion of Takotsubo cardiomyopathy is the re-
versibility of the regional wall motion abnormalities of the
LV that extend beyond a single epicardial vascular distribu-
tion. Characteristically the initial dyskinesia affects the apex
and to various extent the mid-myocardial segments (anterior
and septal segments always appear to be involved, whereas
the mid-cavity posterolateral wall appears less affected). This
is known as the classical “apical ballooning”, and a comple-
mentary characteristic is the presence of basal hyperkinesia,
further contributing to the characteristic morphology.
However, other contraction patterns during the acute phase
of Takotsubo may be present, and identification of other less
common phenotypes (mid-cavity, basal or focal) has been
described. In particular, the mid-cavity type, when seen, is
quite pathognomonic for the disease. The basal or “inverted”
variants (basal akinesis with mid ventricular and apical spar-
ing) has also been reported and is characterized by basal
hypokinesia and apical hypercontractility [21, 22].
Interestingly, the basal pattern has been associated with
pheochromocytoma-induced Takotsubo and a younger age at
presentation [23].
The classical apical variant can be accompanied by a dy-
namic obstruction in the LV outflow tract with or without
systolic anterior motion of the mitral leaflets and/or functional
mitral valve regurgitation. In the early days of diagnosing
Takotsubo, it was not uncommon to misdiagnose these cases
as hypertrophic cardiomyopathy. Characteristic for all
Takotsubo phenotypes is the spontaneous recovery of wall
motion abnormalities to normal or near normal ejection frac-
tion in a matter of days to a few weeks; therefore, repeat
imaging constitutes now a requirement for confirmation of
diagnosis.
Right Ventricular Involvement Biventricular involvement is
much more common than initially appreciated from echocar-
diography studies, due to the ability of CMR to visualize the
RV in its entirety. Several reports showed that in Takotsubo
patients presenting predominantly with ST elevation electro-
cardiogram, RV functional involvement was identified in ap-
proximately half [24, 25]. RV involvement was also associat-
ed with longer hospitalization, worse markers of heart failure
and older age [25].
Atrial Involvement CMR allows additionally for the assess-
ment of the atrial function with the use of left atrial (LA)
functional indexes. Compared with anterior ST elevation
myocardial infarction, Takotsubo patients demonstrated a sig-
nificantly worse LA function as assessed by CMR volumetric
indexes derived from fractional volume changes during the
acute phase of the disease. Impairment of LA performance
seems to be transient in Takotsubo with full recovery seen
during follow-up [26].
Feature Tracking CMR Feature tracking CMR (CMR-FT) is a
novel technique which allows quantification of motion and
strain using standard cine sequences of ventricular functional
protocol. Abnormal global and regional strain patterns during
the acute phase of Takotsubo that improved over time have
been described by 2D echocardiography [27]. CMR-FT has
been utilized to assess the diagnostic and prognostic potential
of atrial involvement in Takotsubo and has demonstrated tran-
sient impairment in left atrial reservoir and conduit functions
[28].
CMR-FT also has a place in assessing dys-synchrony and
rotational mechanics in acute and during the clinical course of
Takotsubo. Essentially desynchrony was shown to be in-
creased in acute phase of Takotsubo, more pronounced in
apical ballooning and seen in recover over time. CMR-FT
may offer a reliable guide to improved pathophysiological
evaluation of Takotsubo through rotational mechanics and
dys-synchrony [29].
Tissue Characterization: Myocardial Oedema
and Inflammation
T2W CMR is the standard imaging technique for detecting
acute myocardial oedema [30, 31]. Black-blood T2W Triple-
IR [32] provides contrast between regional oedema and nor-
mal myocardium due to the dual suppression of the fat and
flowing blood signal. Each tissue type exhibits a characteristic
range of normal T1 and T2 relaxation times at a specific mag-
netic field strength.
Neil et al. found that increased T2W signal intensity, par-
ticularly at the apical cavity in apical Takotsubo patients,
which persisted after 3 months, was inversely related to myo-
cardial strain [33, 34]. The amount of myocardial oedema seen
in acute Takotsubo is unprecedented and causes an acute in-
crease in LV mass [35], which is another helpful diagnostic
feature during acute presentation. Quantitative techniques
such as T1 mapping have confirmed this intensity of the myo-
cardial oedema seen in the acute phase [35, 36]. In a
multicentre study by Eitel et al., myocardial oedema was re-
ported in 81% of patients; this most likely is related to the
variability in time between imaging relative to the acute pre-
sentation or disease onset [37]. We have shown that the myo-
cardial oedema is present in both ballooning and non-
ballooning segments [35] and also involves the right ventricle
[24]. It appears therefore that Takotsubo is characterized by
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pan-myocardial oedema in the acute phase. Longitudinal stud-
ies demonstrated the presence of residual oedema at 4 months
[38•, 39•], and a recent clinical trial further reported that it is
only after 5 months after the acute event that the LVoedema
begins to dissipate [39•].
In the absence of a clear ischaemic or infectious insult, it is
intriguing as to what underlies this intense myocardial oedema
and what could be its cause. In a recent multicentre study, we
showed that compared with control subjects, patients with
Takotsubo cardiomyopathy had greater ultrasmall
superparamagnetic iron oxide particle (USPIO) retention in
both ballooning and non-ballooning LV during the acute
phase. As USPIOs are phagocytosed exclusively by activated
tissue macrophages and not by any other inflammatory cells,
this study demonstrated conclusively that macrophages are the
main cellular protagonists of the myocardial cellular inflam-
mation in acute Takotsubo (in contrast to acute myocarditis
which is lymphocyte-mediated). Additionally, serum
interleukin-6 and chemokine (C-X-C motif) ligand 1 concen-
trations and classic (CD14++CD16−) monocytes were in-
creased, whereas intermediate (CD14++CD16+) and non-
classic (CD14+CD16++) monocytes were reduced in patients
with Takotsubo cardiomyopathy. At 5 months follow-up,
USPIO enhancement was no longer detectable in the LVmyo-
cardium, although elevations in serum interleukin-6 concen-
trations and reductions in intermediate CD14++CD16+ mono-
cytes persisted. Therefore, Takotsubo cardiomyopathy is char-
acterized by a myocardial macrophage inflammatory infil-
trate, changes in the distribution of monocyte subsets and an
increase in systemic pro-inflammatory cytokines. Many of
these changes persisted for at least 5 months, suggesting a
low-grade, chronic inflammatory state [39•]. Furthermore,
post-mortem examination of human hearts from patients
who died during the acute phase of the condition demonstrat-
ed that these macrophages are predominantly of M1, pro-
inflammatory type, as opposed to the reparative M2 type
[40•]. The presence of M1 macrophages and the persistence
of the intermediate (CD14++CD16+) monocyte subset at
5 months follow-up are strongly indicative of lesser repair
and more pro-inflammatory state compared with similar
stages of patients with acute myocardial infarction. This offers
the explanation for the low-grade, chronic inflammatory sub-
strate and the evolution of acute Takotsubo into a long-term
heart failure phenotype [41•].
Further evidence of the different systemic inflammato-
ry activation in Takotsubo and acute coronary syndromes
has been demonstrated by Santoro et al. who compared
circulating cytokine levels in acute and subacute phase of
Takotsubo and acute coronary syndromes. Increased
levels of anti-inflammatory interleukins were found in
acute phase of Takotsubo, while high levels of IL-6 were
found in acute and subacute phase of acute coronary syn-
dromes [42].
These demonstrated differences in pro-inflammatory medi-
ator profiles in the two conditions seem promising to research
more targeted and novel therapeutic options.
Apico-basal myocardial oedema as evidenced by increased
T2W signal in CMR has been shown to be correlating with the
ischaemic Wellens type ECG changes seen in Takotsubo. The
dynamic Twaves change, and QTc prolongation likely reflects
the repolarisation dispersion in apical and basal segments sec-
ondary to myocardial oedema [43].
Early and Late Gadolinium Enhancement
The use of EGE sequence, performed within 2 min after con-
trast agent infusion, can reveal intra-cavitary LV/RV thrombus
which appears as a low signal intensity (no gadolinium up-
take) relative to the intermediate signal of the myocardium and
high intensity signal of the blood pool [44].
Late gadolinium enhancement has been one of the most
studied areas of CMR in Takotsubo. Initially, it was believed
that lack of LGE was necessary to diagnose Takotsubo and
would thus help differentiate it from myocardial infarction,
where LGE is always present in some degree/pattern, and
myocarditis, where 88% of patients show a patchy type of
LGE [11, 45]. Eventually, some isolated reports, and later
on, more significant studies, showed that LGE can be seen
in patients diagnosed with Takotsubo cardiomyopathy [37,
46, 47]. When the pattern of LGE overlaps with that seen in
other conditions (ischemia, myocarditis), two possibilities re-
main as it is very difficult to say with certainty whether the
LGE is part of the acute presentation (and therefore represents
Takotsubo-inflicted myocardial injury) or whether it reflects a
previous and different pathophysiology in the same patient
(and therefore is independent of the Takotsubo cardiomyopa-
thy altogether). Corroboration between clinical presentation,
ECG, imaging and biomarker findings are essential to make
the correct diagnosis. Figure 1 a and b demonstrate an LGE
pattern that overlaps with that seen in myocarditis or non-
ischemic cardiomyopathies. Figure 1 c and d demonstrate pat-
terns which can be seen in other types of non-ischemic
cardiomyopathies.
However, in some rare occurrences, the pattern of LGE
seen is uniquely observed in Takotsubo: a distinctive
transmural band appearing at the hinge points between the
dyskinetic ballooning segments and the hypercontractile seg-
ments (Fig. 1e–f)— probably representing high shear forces at
the demarcating border between dyskinetic and hypercontrac-
tile myocardium resulting in traumatic myocyte death.
The importance of detecting LGE in Takotsubo patients
relies on the observed association between the presence of
LGE and poorer prognosis in both ischemic and non-
ischemic cardiomyopathies [47]. In a series of 20 patients with
Takotsubo cardiomyopathy, it was observed that LGE was
associated with an increased frequency of cardiogenic shock
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Fig. 1 Note: This data is mandatory. Please provide.
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and longer duration to ECG normalization [48]. In that same
series and in another study, it was also observed that LGE-
positive patients took longer to recover from the wall motion
abnormalities [48, 49].
However, the main expected finding in the vast majority of
clinical Takotsubo cases should be the absence of any LGE,
which should remain a strong supporting finding for establish-
ing the diagnosis.
Cardiac Energetic Status
Cardiac energetics (the PCr/γATP ratio obtained non-
invasively by 31P-magnetic resonance spectroscopy) is se-
verely reduced acutely in Takotsubo and only partly recovers
by 4 months [35]. Furthermore, in a landmark cardiac pheno-
typing study, we demonstrated that patients with a prior epi-
sode of Takotsubo continue to have a significant degree of
impairment in the cardiac energetic status long-term, which
most likely represents the metabolic substrate of the heart
failure phenotype that these patients appear to develop [41•].
Complications and Long-Term Prognosis
Possible complications in Takotsubo in the acute setting
which include right ventricular involvement (18–34%), left
heart failure with or without pulmonary oedema (12–45%),
dynamic LVOTobstruction (10–25%), mitral valve regurgita-
tion (14–25%), ventricular arrhythmias (4–9%), intramural
thrombus(2–8%), pericardial effusion(< 1%), stroke [50], LV
free wall rupture (< 1%) and death [49, 50, 51•] have been
described in the acute setting.
The long-term prognosis of patients with Takotsubo was
initially thought to be favourable because of LV function re-
covery observed within several weeks to months [37]. Several
small studies reported 15–17% all-cause mortality after 2.9–
4.7 years in Takotsubo patients [52, 53]. The long-term mor-
tality due to cardiovascular and non-cardiac causes are well
documented [54–56]. Cardiogenic shock has been shown to
be an important predictor in short- and long-term mortality in
Takotsubo. Almendro et al. describe the subgroup of patients
with cardiogenic shock as a high-risk phenotype with cluster-
ing of factors predisposing to heart failure. However, counter-
intuitively, long-term mortality in this subgroup of patients
with cardiogenic shock was driven mainly by non-cardiac
causes. This has raised the possibility of a vulnerable pheno-
type prone to heart failure [57, 58]. Even though large registry
data [34] have now convincingly confirmed the poor long-
term prognosis of Takotsubo patients, the actual cause of death
in Takotsubo patients remains to be defined. This information
will be instrumental in guiding therapies which address
survival.
Conclusions
CMR offers a comprehensive, safe and reproducible assess-
ment of the myocardial functional and anatomical properties,
as well as of some of the potential complications of the syn-
drome, and has a complementary and additive role to the di-
agnosis of Takotsubo cardiomyopathy, once initial cardiac
catheterisation has been carried out. As Takotsubo remains a
diagnosis of exclusion, the information obtained from CMR
adds in the workup and its differentiation from other acute
entities with similar clinical presentation. Further large-scale
studies are required to elucidate the exact clinical and prog-
nostic value of CMR parameters in the management of the
disease.
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